Stay updated on NKTR-214 Plus Nivolumab in Sarcoma Clinical Trial
Sign up to get notified when there's something new on the NKTR-214 Plus Nivolumab in Sarcoma Clinical Trial page.

Latest updates to the NKTR-214 Plus Nivolumab in Sarcoma Clinical Trial page
- Check7 days agoChange DetectedThe NCT03282344 page now displays the study record, including its treatment plan, eligibility criteria, outcome measures, locations, recruitment status, and record dates.SummaryDifference50%

- Check14 days agoChange DetectedThe footer now identifies the ClinicalTrials.gov site revision as v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check21 days agoChange DetectedA banner announces NIH website transition updates and says the agency is using “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check28 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check35 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changes from v3.7.0 to v3.7.1; the page otherwise remains a 403 error.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record content, indicating access restrictions or a site issue; as a result, sponsor, locations, eligibility criteria, and related study information are no longer visible and the page shows a standard error layout.SummaryDifference19%

Stay in the know with updates to NKTR-214 Plus Nivolumab in Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the NKTR-214 Plus Nivolumab in Sarcoma Clinical Trial page.